Tactical Therapeutics, Inc., an emerging growth oncology drug development company, presented results of two Phase IB trials of its lead drug Carboxyamidotriazole Orotate (CTO, PRAVITNIB) at the American Society of Clinical Oncology meeting in Chicago.
Tactical is in the process of developing its patented drug, CTO, in patients with malignant glioma and glioblastoma (GBM). Treatment options are limited for GBM, which grows rapidly and spreads to the brain, making complete surgical resection difficult. GBM is highly resistant to DNA-modifying drugs and the standard combination of surgery, radiotherapy and chemotherap results in an overall survival of 12-15 months. As such, there remains a critical unmet need.
The results of the study showed good tolerability and clinical efficacy, which are particularly promising as this patient population represents those with the highest unmet need in GBM.
Tactical Therapeutics has developed CTO for the orphan GBM and malignant glioma. GBM exhibits aggressive molecular heterogeneity, drug resistance, immunosuppression and delivery challenges. CTO inhibits non-voltage dependent calcium signal transduction that modulates multiple signaling pathways that are active in GBM and crosses the blood brain barrier.
The company plans to move forward into two Phase II/III registration directed clinical trials as a potential new treatment for GBM in newly-diagnosed and recurrent GBM patients.
To learn more about this company, and to receive an Executive Summary, e-mail us at email@example.com
To read more about Tactical Therapeutics, please visit www.tacticaltherapeutics.com